Association of Polymorphisms in MCP-1, CCR2, and CCR5 Genes with the Risk and Clinicopathological Characteristics of Prostate Cancer

Abstract

The aim of our study was to determine the effect of monocyte chemotactic protein-1 (MCP-1), CC chemokine receptor 2 (CCR2), and CC chemokine receptor 5 (CCR5) gene polymorphisms on the susceptibility and clinicopathological characteristics of prostate cancer. Genotyping was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method in 156 histopathologically confirmed prostate cancer patients and 152 healthy subjects. Individuals with AA genotype or at least one A allele of CCR2 V64I gene polymorphism had a higher risk for prostate cancer as compared with those with GG genotype (p = 0.010 and p = 0.028, respectively). CCR5 Delta 32/wt genotype and CCR5 Delta 32 allele were also found to be involved in the susceptibility to prostate cancer (p = 0.028 and p = 0.030, respectively). However, there was no significant association between MCP-1-2518 A/G gene polymorphism and prostate cancer risk. Prostate cancer patients carrying AA genotype or at least one A allele of CCR2 V64I had significantly increased risk for high stage disease (p = 0.002 and p = 0.039, respectively) and metastasis (p = 0.004 and p = 0.022, respectively). The CCR2 A allele (64I allele) was significantly associated with high T stage (p = 0.001) and metastasis (p = 0.005) as compared with CCR2 G allele (64V allele). Our data indicate that gene polymorphism of CCR2 V64I may influence the susceptibility and clinicopathological characteristics of prostate cancer and CCR5 Delta 32 allele may also be an important risk factor for prostate cancer in Turkish men population.